BioCentury
ARTICLE | Financial News

Merus raising EUR 72.8M series C

August 27, 2015 12:36 AM UTC

Merus B.V. (Utrecht, the Netherlands), which develops bispecific antibodies for cancer, raised an undisclosed amount of money in the first tranche of a EUR 72.8 million ($83.6 million) series C round led by new investors Sofinnova Ventures and Novo A/S. Other new investors included RA Capital; Rock Springs Capital; Tekla Capital Management; and an undisclosed investor. They joined existing investors Novartis Venture Fund; Johnson & Johnson Innovation-JJDC Inc.; Pfizer Venture Investments; Bay City Capital; LSP Life Sciences Partners; and Aglaia Oncology Fund.

Merus' lead product, MCLA-128, is in Phase I/II testing for solid tumors expressing epidermal growth factor receptor 2 ( HER2; EGFR2; ErbB2; neu). The antibody-dependent cell-mediated cytotoxicity (ADCC)-enhanced human common light chain bispecific IgG1 antibody targets HER2 and HER3. ...